Figure 1.
Continuous carfilzomib and TG02 co-treatment results in at least additive cell death. Cells were plated at a density of 0.25 × 106 cells/mL and treated with the indicated concentrations of (A) carfilzomib, (B) TG02 or the (C) combination for 24 hours. (D) Cells were co-treated with carfilzomib (IC10 and IC50 concentrations) and TG02 for 1 hour, washed and then treated with TG02 for 23 hours. Cell death was determined via Annexin–V–FITC/PI flow cytometry. Data are presented as mean +/− SEM of at least 3 independent experiments. IC50 and IC10 significance are indicated above and below the mean values, respectively. (E) Ficoll isolated buffy coat from a myeloma patient BM aspirate was collected and washed with PBS. Plasma cells were either treated in the presence of buffy coat cells (MM53 and MM55) or CD138+ plasma cells were isolated and treated (MM54). Twenty-four hour apoptosis was determined by staining with anti-CD38, anti-CD45, and Annexin V-FITC. *p > 0.05, **p > 0.01, ***p > 0.001.